MRK | Weekly | Haru Insights

Merck’s Phase 3 success for tulisokibart in moderate-to-severe ulcerative colitis and FDA approvals for new KEYTRUDA indications in triple-negative breast cancer and muscle-invasive bladder cancer represent major near-term catalysts with clear commercial implications.
The ongoing U.S. House Select Committee on China investigation into Merck’s clinical trial activities in Xinjiang and military-affiliated hospitals has emerged as a critical geopolitical risk, potentially impacting regulatory trust, global operations, and investor sentiment.

Merck’s diversified pipeline momentum—driven by robust Phase 3 data for tulisokibart—signals a powerful shift beyond KEYTRUDA dependency, demonstrating genuine innovation across immunology and oncology.
The successful deployment of the IDVYNSO™ access program showcases Merck’s rare ability to merge patient-centric care with scalable commercial execution, enhancing brand loyalty and public trust.
Strategic alliances with Moderna, Bristol Myers Squibb, and other industry leaders reinforce Merck’s elite status as a collaborative powerhouse in cutting-edge therapeutic development.
The integration of Cidara, despite a large $9.0 billion charge, reflects bold, long-term thinking to secure transformational pipeline assets in antifungal and immuno-oncology—high-risk, high-reward execution.
Merck’s enduring presence in top-tier ETFs like PPH and SCHD underscores deep institutional confidence, validating its role as a stable, high-quality cornerstone in modern healthcare portfolios.

Merck & Co., Inc. (MRK)[Tv]